首页> AIDS research and therapy> Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

导出 OA

翻译打印收藏纠错

第一作者： Frank,Mulindwa

第一单位： Capacity Building Program, Makerere University Infectious Diseases Institute, Kampala, Uganda. fmulindwa@idi.co.ug.;Global Health Institute, Antwerp University, Antwerp, Belgium. fmulindwa@idi.co.ug.

作者： Frank,Mulindwa ^[1] ; Barbara,Castelnuovo ^[2] ; Nele,Brusselaers ^[3] ; Martin,Nabwana ^[4] ; Robert,Bollinger ^[5] ; Allan,Buzibye ^[2] ; Eva Laker,Agnes Odongpiny ^[2] ; Ronald,Kiguba ^[6] ; Jean-Marc,Schwarz ^[7]

作者单位： Capacity Building Program, Makerere University Infectious Diseases Institute, Kampala, Uganda. fmulindwa@idi.co.ug.;Global Health Institute, Antwerp University, Antwerp, Belgium. fmulindwa@idi.co.ug. ^[1] Capacity Building Program, Makerere University Infectious Diseases Institute, Kampala, Uganda. ^[2] Global Health Institute, Antwerp University, Antwerp, Belgium.;Centre for Translational Microbiome Research, Department of Microbiology, Tumour and Cell Biology, Karolinska University, Stockholm, Sweden. ^[3] Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda. ^[4] School of Medicine, Johns Hopkins University, Baltimore, USA. ^[5] Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda. ^[6] School of Medicine, University of California San Francisco, San Francisco, USA.;Department of Basic Sciences, Touro University California College of Osteopathic Medicine, Vallejo, CA, USA. ^[7]

关键词 Dolutegravir HOMA Insulin resistance Pancreatic beta cell function Type 2 diabetes Mellitus